Recent Advances in Parkinson's Disease
Specificaties
Gebonden, blz.
|
Engels
Elsevier Science |
e druk, 2020
ISBN13: 9780444642608
Rubricering
Onderdeel van serie
Progress in Brain Research
Levertijd ongeveer 8 werkdagen
Samenvatting
Recent Advances in Parkinson´s Disease Research, Volume 252, represents a follow-up on two previous volumes presented in the Progress in Brain Research series, Volumes 193 and 193, both published in 2010. It contains a collection of overview articles written by leading researchers in Parkinson's, discussing the most important advances made in basic, translational and clinical research. Topics of note in this new release include What can we learn from iPS cell models of PD, What can we learn from animal models of PD?, Molecular basis of selective neuronal vulnerability in PD, Role of innate and adaptive immunity in Parkinson´s disease, and much more.
Specificaties
Inhoudsopgave
<p>What we can learn from iPSC-derived cellular models of Parkinson’s disease?</p> <p>Maria Claudia Caiazza, Charmaine Lang and Richard Wade-Martins</p> <p>2. Animal models for preclinical Parkinson’s research: An update and critical appraisal</p> <p>M. Angela Cenci and Anders Björklund</p> <p>3. Selective neuronal vulnerability in Parkinson’s disease</p> <p>Patricia Gonzalez-Rodriguez, Enrico Zampese and D. James Surmeier</p> <p>4. Mechanisms of alpha-synuclein toxicity: An update and outlook</p> <p>Inês Caldeira Brás, Mary Xylaki and Tiago Fleming Outeiro</p> <p>5. The role of glia in Parkinson’s disease: Emerging concepts and therapeutic applications</p> <p>Katarzyna Z. Kuter, M. Angela Cenci and Anna R. Carta</p> <p>6. Innate and adaptive immune responses in Parkinson's disease</p> <p>Aubrey M. Schonhoff, Gregory P. Williams, Zachary D. Wallen, David G. Standaert and Ashley S. Harms</p> <p>7. Pathways of protein synthesis and degradation in PD pathogenesis</p> <p>Rebekah G. Langston and Mark R. Cookson</p> <p>8. Endosomal sorting pathways in the pathogenesis of Parkinson’s disease</p> <p>Lindsey A. Cunningham and Darren J. Moore</p> <p>9. New players in basal ganglia dysfunction in Parkinson's disease</p> <p>Sara Meoni, Rubens Gisbert Cury and Elena Moro</p> <p>10. Prodromal PD: A new nosological entity</p> <p>Eva Schaeffer, Ronald B. Postuma and Daniela Berg</p> <p>11. The gut microbiome in Parkinson’s disease: A culprit or a bystander?</p> <p>Ali Keshavarzian, Phillip Engen, Salvatore Bonvegna and Roberto Cilia</p> <p>12. Novel approaches to counter protein aggregation pathology in Parkinson's disease</p> <p>Simon R.W. Stott, Richard K. Wyse and Patrik Brundin</p> <p>13. Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience</p> <p>Tom Foltynie and Dilan Athauda</p> <p>14. Basal ganglia oscillations as biomarkers for targeting circuit dysfunction in Parkinson's disease</p> <p>Per Petersson, Andre</p>